Head-to-head evidence
BPI-7711 vs Lazertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
BPI-7711
Developed by Beta Pharma, Inc.
NCT03812809 · Phase 2 · completed
The trial was an open-label, single-arm study of 226 patients receiving BPI-7711, with no randomized control group for comparison. Its primary endpoint was objective response rate by independent RECIST 1.1 review. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Lazertinib
Marketed by Johnson & Johnson and partners
NCT04248829 · Phase 3 · completed
The trial randomized 393 participants to lazertinib or an active gefitinib control and used quadruple masking, with investigators and outcome assessors blinded. Its primary clinical endpoint, progression-free survival, favored lazertinib numerically, but statistical significance is not reported, so the result cannot be classified as definitively met.
Next expected readout: December 2026 · NCT05463224 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPI-7711's landscape · Lazertinib's landscape